Vasopressin News and Research

RSS

Ikaria Holdings acquires NDA and IND application for LUCASSIN drug

Ikaria Holdings, Inc. announced today that it has acquired the New Drug Application (NDA) and the Investigational New Drug (IND) application to LUCASSIN® (terlipressin for injection) from Orphan Therapeutics, assuming all future development and ownership of the drug in North America and Australia.

31 Mar 2010

Genetic accident in sea provides new insight into diabetes: New research

A genetic accident in the sea more than 500 million years ago has provided new insight into diabetes, according to research from Queen Mary, University of London.

23 Mar 2010

Researchers identify a novel way to study species-specific reproductive behavior

Researchers at the California Institute of Technology (Caltech) and the University of California, San Diego (UCSD) have discovered that injecting a simple hormone into leeches creates a novel way to study how hormones and the nervous system work together to produce species-specific reproductive behavior.

17 Mar 2010

Shock: Norepinephrine favored over dopamine

Physicians treating patients with shock should consider norepinephrine instead of dopamine as a tool for stabilizing blood pressure, according to an editorial in the March 4, 2010, issue of the New England Journal of Medicine (NEJM).

3 Mar 2010

Hormone vasopressin helps brain differentiate between familiar and new scents

The study, published in the journal Nature, suggests that when the hormone fails to function, animals are unable to recognise other individuals from their scent.

25 Feb 2010

Pivotal Research to study investigational drug for menstrual cramps

A leading clinical research center in Peoria has joined an international research program to study an investigational drug designed as a possible treatment for painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States.

10 Feb 2010

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.

2 Feb 2010

Salt Lake City research center joins international drug trial program for painful menstrual cramps

A leading clinical research center in Salt Lake City has joined an international trial program to test an experimental new drug designed to treat painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States. Although not life threatening, dysmenorrhea can be debilitating and psychologically taxing and is one of the leading causes of absenteeism from work and school.

12 Jan 2010

Researchers study VA111913 drug as a possible treatment for dysmenorrhea

A leading clinical research center in Austin has joined an international research program to study an investigational drug designed as a possible treatment for painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States.

12 Jan 2010

The neurobiology of music perception and production related to the pathways affecting intrinsic attachment behavior?

Music is social communication between individuals - humming of lullabies attach infant to parent and singing or playing music adds croup cohesion. The neurobiology of music perception and production is likely to be related to the pathways affecting intrinsic attachment behavior, suggests a resent Finnish study. The study gives new information about genetic background of musical aptitude.

26 May 2009

2 genes influence social behavior, visual-spatial performance in people with Williams syndrome

Unraveling the genetics of social behavior and cognitive abilities, researchers at the University of Utah and the Salk Institute for Biological Studies have traced the role of two genes,GTF2I and GTF2IRD, in a rare genetic disorder known as Williams Syndrome.

11 Feb 2009

Protein that regulates hormones critical to women's health found in pituitary

University of Wisconsin-Madison researchers have solved the mystery surrounding a "rogue protein" that plays a role in the release of neurotransmitters and hormones in the brain.

12 Jan 2009

Potential new targets for antidepressants

The news about antidepressant medications over the past several years has been mixed. The bad news from large multicenter studies such as STAR*D is that current antidepressant medications are effective, but not as effective as one might hope. Thus, there is a significant need for new treatment mechanisms for depression. On that front, there has been mixed news as well.

27 Aug 2008

Desmopressin for bed-wetting linked to convulsions in children

Australian authorities have issued a warning regarding a drug sometimes used to treat primary nocturnal enuresis (bed-wetting) in children.

3 Aug 2008

FDA advisory committee recommends approval of Tolvaptan for hyponatremia

The U.S. Food and Drug Administration (FDA) Advisory Committee on Cardiovascular and Renal Drugs voted to recommend the approval of tolvaptan, Otsuka Pharmaceutical Development & Commercialization, Inc.'s (OPDC) investigational treatment for patients with hyponatremia.

25 Jun 2008

Caution on use of Vasopressin in septic shock

Vasopressin should be used with great caution for the treatment of hypotension in septic shock, according to results from an international research team published in the online open access journal Critical Care.

14 Dec 2007

A new fast-melting oral formulation of desmopressin

Vande Walle and colleagues performed this study to determine the pharmacodynamic properties as well as the safety and tolerability of a new oral lyophilisate formulation of desmopressin (in single doses of 30, 60, 120, 240, 360 or 480 µg) in children with known primary nocturnal enuresis (PNE).

3 May 2006

New drug lixivaptan reduces excess fluid build-up in patients with congestive heart failure

Researchers believe they may have identified a new agent to reduce the excess fluid build-up in patients with congestive heart failure, one that avoids the relative sodium-depleting effects of diuretics, now the most commonly used drugs for this purpose.

3 May 2006

Anabolic steroids flip the adolescent brain's switch for aggression

Anabolic steroids not only make teens more aggressive, but may keep them that way into young adulthood. The effect ultimately wears off but there may be other, lasting consequences for the developing brain.

27 Feb 2006

Steroids trigger long lasting aggression in teens

According to a U.S. study steroids may have a lasting effect on teenagers' brains, and could even flip the adolescent brain's switch for aggression which may last for at least two years.

27 Feb 2006